Cytokinetics, Incorporated announced that Myqorzo (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA)… read more.
Altamira Therapeutics Ltd. announced that its associate company Altamira Medica has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Bentrio nasal spray… read more.
Emergency Medicine & Intensive Care
Hansa Biopharma AB announced the submission of a Biologics License Application (BLA) to the FDA for imlifidase. The Company is requesting priority review of the BLA for the… read more.
BD (Becton, Dickinson and Company) announced the launch of the BD Surgiphor Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive… read more.
Abeona Therapeutics Inc. announced the first patient treatment with FDA-approved Zevaskyn (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive… read more.
Guardant Health Inc. announced new data demonstrating that its Guardant Reveal blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months… read more.
Organon announced that it has entered into an agreement with Laborie Medical Technologies Corp., a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA… read more.
Chugai and Renalys Pharma, Inc. announced positive topline results from its Phase III clinical study of sparsentan (RE 021), an orally administered dual endothelin and angiotensin II receptor… read more.
GSK plc announced that the FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients… read more.
Abivax SA a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases,… read more.
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response… read more.
A new doctoral dissertation from the University of Vaasa, Finland, argues that healthcare cybersecurity will remain fragile unless technology, humans and organisational processes are treated as a single… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
